title: Precipitation of porphyria cutanea tarda by imatinib mesylate?
authors.forename: Aloysius Y L
authors.initials: AY
authors.lastname: Ho
authors.forename: Allan
authors.initials: A
authors.lastname: Deacon
authors.forename: Genevieve
authors.initials: G
authors.lastname: Osborne
authors.forename: Ghulam J
authors.initials: GJ
authors.lastname: Mufti
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D017119:Porphyria Cutanea Tarda / Q000139:chemically induced*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl